Aeterna Zentaris Inc. - Report of Foreign Issuer (6-K)

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of August 2008

Commission File No. 000-30752

AETERNA ZENTARIS INC.

1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F /X/ Form 40-F / /

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes / / No /X/

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION

1. Press Release dated August 6, 2008: AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008

[AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.

Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aezsinc.com

 PRESS RELEASE
 For immediate release

AETERNA ZENTARIS TO ANNOUNCE SECOND QUARTER 2008 FINANCIAL AND OPERATING RESULTS ON AUGUST 12, 2008

QUEBEC CITY, CANADA, AUGUST 6, 2008 - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX:
AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its second quarter 2008 financial and operating results after market close on Tuesday, August 12, 2008. The Company will host a conference call and webcast to discuss these results later that same day at 4:30
p.m., Eastern Time.

Participants may access the conference call by dialing the following numbers:
416-644-3430, 514-807-8791 or 800-814-4862. They may also access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section. A replay of the webcast will also be available on the Company's website for a period of 30 days.

ABOUT AETERNA ZENTARIS INC.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

INVESTOR RELATIONS
Dennis Turpin, CA
Senior Vice President and Chief Financial Officer (908) 626-5503
dturpin@aezsinc.com

MEDIA RELATIONS
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406 pburroughs@aezsinc.com

-30-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: August 6, 2008 By: /s/ Dennis Turpin
--------------------- ----------------------------------------------
 Dennis Turpin
 Senior Vice President, Chief Financial Officer

Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024